Jasper van Geel
YOU?
Author Swipe
View article: Comparative analysis of FES-PET/CT and FDG-PET/CT in patients with ER-positive metastatic invasive lobular breast cancer
Comparative analysis of FES-PET/CT and FDG-PET/CT in patients with ER-positive metastatic invasive lobular breast cancer Open
FES-PET/CT and FDG-PET/CT have a similar detection rate in mILC, and FDG-PET/CT should be used for first-step imaging. However, as more metastases are visible on FES-PET/CT in a considerable part of mILC patients, in case of doubt, an addi…
View article: Clinicopathological and molecular characterization of inflammatory breast cancer, the prospective INFLAME registry study
Clinicopathological and molecular characterization of inflammatory breast cancer, the prospective INFLAME registry study Open
View article: Intrapatient 16α-[<sup>18</sup>F]Fluoro-17β-Estradiol PET Heterogeneity as a Prognostic Factor for Endocrine Therapy Response and Survival in Patients with Estrogen Receptor–Positive Metastatic Breast Cancer
Intrapatient 16α-[<sup>18</sup>F]Fluoro-17β-Estradiol PET Heterogeneity as a Prognostic Factor for Endocrine Therapy Response and Survival in Patients with Estrogen Receptor–Positive Metastatic Breast Cancer Open
Intrapatient heterogeneity of estrogen receptor (ER) expression on 16α-[18F]fluoro-17β-estradiol ([18F]FES) PET is related to outcome in patients with ER-positive metastatic breast cancer (MBC), but a validated and pr…
View article: Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer
Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer Open
Understanding which patients with human epidermal growth factor receptor 2 (HER2)-negative or -low metastatic breast cancer (MBC) benefit from HER2-targeted strategies is urgently needed. We assessed the whole-body heterogeneity of HER2 ex…
View article: Correlation between Histopathological Prognostic Tumor Characteristics and [18F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer
Correlation between Histopathological Prognostic Tumor Characteristics and [18F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer Open
Background: In metastatic breast cancer (MBC), [18F]fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG-PET/CT) can be used for staging. We evaluated the correlation between BC histopathological characteristics an…
View article: Shared decision-making performance of general practice residents: an observational study combining observer, resident, and patient perspectives
Shared decision-making performance of general practice residents: an observational study combining observer, resident, and patient perspectives Open
Background Shared decision making (SDM) is considered fundamental to person-centred care. However, applying SDM may be a challenge for residents in general practice, since it is a complex competence that requires the integration of knowled…
View article: PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial
PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial Open
View article: Molecular imaging as biomarker for treatment response and outcome in breast cancer
Molecular imaging as biomarker for treatment response and outcome in breast cancer Open
Molecular imaging, such as positron emission tomography (PET), is increasingly used as biomarker to predict and assess treatment response in breast cancer. The number of biomarkers is expanding with specific tracers for tumour characterist…
View article: Clinical Validity of 16α-[<sup>18</sup>F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer
Clinical Validity of 16α-[<sup>18</sup>F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer Open
PURPOSE Determining the estrogen receptor (ER) status is essential in metastatic breast cancer (MBC) management. Whole-body ER imaging with 16α-[ 18 F]fluoro-17β-estradiol positron emission tomography ([ 18 F]FES-PET) is increasingly used …